Stable cell line development (CLD) for recombinant glycan proteins – despite its 40-year history – still suffers due to unexpected and vulnerable outputs caused by the influence of unpredictable traits of the base host cell line. However, recently – through the CHOZN-GS system – we observe better CLD performance than other CHO systems in terms of time, cost, titer, stability, and scale-up, due in part to its robust genetic stability. In particular, we find that optimization of key CLD process factors at an early stage has a large impact on the final outcome. In this webinar, we will share how CLD strategies can be flexibly optimized under given conditions through an understanding of the scientific context.
In this webinar, you will learn:
Dr. Young Min Oh
Since 2017, Dr. Young Min has worked for GI Innovation, Inc. as the head of SMART division and co-founder. His main activity is the construction of SMART platform technology, which is comprised of the screening & selection method for an 'easy-to-express protein' structure with the therapeutic function of a target disease and its stable high production cell line development. He holds a doctorate degree in Immunology from POSTECH, South Korea, where he focused on the study of the transcriptional regulatory network during inflammation through comparative genomics and systems biology interpretation.